https://orcid.org/0000-0002-4054-2563
Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Priyanka Gaitonde, Viktor Chirikov, Sneha Kelkar & Bengt Liljas. (2022) Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors. Cancer Management and Research 14, pages 3421-3435.
Read now
Read now
Nathaniel Smith, An-Chen Fu, Tim Fisher, Dennis Meletiche & Vivek Pawar. (2022) Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints. Journal of Medical Economics 25:1, pages 1-6.
Read now
Read now
Michael Patrick Lux, Oriana Ciani, William C N Dunlop, Andrea Ferris & Michael Friedlander. (2021) The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?. Cancer Management and Research 13, pages 8457-8471.
Read now
Read now
Articles from other publishers (7)
Holly L. Cranmer, Gemma E. Shields & Ash Bullement. (2023) An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology. Applied Health Economics and Health Policy 21:3, pages 385-394.
Crossref
Crossref
Eugena Stamuli, Sorcha Corry & Petter Foss. (2023) Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis. International Journal of Technology Assessment in Health Care 39:1.
Crossref
Crossref
Elaine Julian, Fabrizio Gianfrate, Oriol Sola-Morales, Peter Mol, Jean-François Bergmann, Tomas Salmonson, Ansgar Hebborn, Mathilde Grande & Jörg Ruof. (2022) How can a joint European health technology assessment provide an ‘additional benefit’ over the current standard of national assessments?. Health Economics Review 12:1.
Crossref
Crossref
Yitong Wang, Tingting Qiu, Mateusz Nikodem, Clément Francois & Mondher Toumi. (2022) A systematic literature review of revealed preferences of decision-makers for recommendations of cancer drugs in health technology assessment. International Journal of Technology Assessment in Health Care 38:1.
Crossref
Crossref
Carolina Zampirolli Dias, Brian Godman, Ludmila Peres Gargano, Pâmela Santos Azevedo, Marina Morgado Garcia, Maurílio Souza Cazarim, Laís Lessa Neiva Pantuzza, Nelio Gomes Ribeiro-Junior, André Luiz Pereira, Marcus Carvalho Borin, Isabella de Figueiredo Zuppo, Roberto Iunes, Tomas Pippo, Renata Curi Hauegen, Carlos Vassalo, Tracey-Lea Laba, Steven Simoens, Sergio Márquez, Carolina Gomez, Luka Voncina, Gisbert W. Selke, Livio Garattini, Hye-Young Kwon, Jolanta Gulbinovic, Aneta Lipinska, Maciej Pomorski, Lindsay McClure, Jurij Fürst, Rosana Gambogi, Carla Hernandez Ortiz, Vânia Cristina Canuto Santos, Denizar Vianna Araújo, Vânia Eloisa Araujo, Francisco de Assis Acurcio, Juliana Alvares-Teodoro & Augusto Afonso Guerra-Junior. (2020) Integrative Review of Managed Entry Agreements: Chances and Limitations. PharmacoEconomics 38:11, pages 1165-1185.
Crossref
Crossref
Hansoo Kim, Danny Liew & Stephen Goodall. (2020) Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy. British Journal of Clinical Pharmacology 86:9, pages 1703-1710.
Crossref
Crossref
Andriy Krendyukov & Sreekanth Gattu. (2020) Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology. Pharmaceutical Medicine 34:2, pages 103-112.
Crossref
Crossref